Asta Pharma Aktiengesellschaft

Peter Hankofer

Jurgen Engel

Peter Hilgard

Wolfgang Schumacher

Henri Brunner

Rainer Voegeli

Friedrich Maiterth

Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N-CR.sub.2 &lt; forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural part --CR.sub.2 &lt; represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 &lt; represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also being possible for the phenyl ring of this group R.sub.2 to be substituted by hydroxy, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -alkyl, C.sub.2 -C.sub.6 -alkanoyloxy or halogen; the radicals R.sub.3 and R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl and X stands for the equivalent of a physiologically acceptable anion or X can also be a water molecule, where in the latter case the missing negative charge is saturated by a corresponding physiologically acceptable acid anion, where in the case of platinum(II) complexes, two of the groups X are absent.

Ethylene-substituted phenylalkylethylenediamine-platinum (II or IV)

Antitumor acting platinum(II or IV) complexes of the general formula ##STR1## where B represents a phenyl-C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted in the phenyl nucleus by the radical R.sub.1 and R.sub.1 is hydrogen, halogen, trihalogen methyl, C.sub.1 -C.sub.6 -alkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or C.sub.2 -C.sub.6 -alkanoyloxy or where B together with the structural part H.sub.2 N--CR.sub.2 &lt;forms a tetrahydroisoquinoline radical, if B contains benzyl and R.sub.2 hydrogen and the benzyl radical in the 2-position contains the CH.sub.2 -radical or where B together with the structural part --CR.sub.2 &lt; represents a tetrahydronaphthyl radical in which one CH.sub.2 group is optionally replaced by oxygen, or where B together with the structural part --CR.sub.2 &lt; represents a decahydronaphthyl radical or an indanyl radical; R.sub.2 represents hydrogen, C.sub.1 -C.sub.6 -alkyl, phenyl or phenyl-C.sub.1 -C.sub.4 -alkyl, it also being possible for the phenyl ring of this group R.sub.2 to be substituted by hydroxy, C.sub.1 -C.sub.4 -alkoxy, C.sub.1 -C.sub.4 -alkyl, C.sub.2 -C.sub.6 -alkanoyloxy or halogen; the radicals R.sub.3 and R.sub.4 are the same or different and represent hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl and X stands for the equivalent of a physiologically acceptable anion or X can also be a water molecule, where in the latter case the missing negative charge is saturated by a corresponding physiologically acceptable acid anion, where in the case of platinum(II) complexes, two of the groups X are absent.

Ethylene-substituted phenylalkylethylene-diamine-platinum (II or IV)

Growing community of inventors

Koln, Germany

Peter Hankofer